Advances in the area of cardiorenal medicine: clinical research highlights from selected papers published in NDT.
作者信息
Georgianos Panagiotis I, Agarwal Rajiv
机构信息
Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
出版信息
Nephrol Dial Transplant. 2022 Aug 22;37(9):1595-1597. doi: 10.1093/ndt/gfac130.
Abstract
摘要
相似文献
1
Advances in the area of cardiorenal medicine: clinical research highlights from selected papers published in NDT.心肾医学领域的进展：发表于《肾透析与移植》的精选论文的临床研究亮点
Nephrol Dial Transplant. 2022 Aug 22;37(9):1595-1597. doi: 10.1093/ndt/gfac130.
2
Cardiorenal medicine in the changing health system.不断变化的卫生系统中的心脏肾医学。
J Ren Care. 2012 Jun;38(2):65-8. doi: 10.1111/j.1755-6686.2012.00307.x.
3
Advances in Cardiorenal Medicine: The Year 2023 in Review.心脏肾医学进展：2023年回顾
Cardiorenal Med. 2024;14(1):123-128. doi: 10.1159/000537785. Epub 2024 Feb 14.
4
[Cardiorenal syndrome].[心肾综合征]
Med Klin Intensivmed Notfmed. 2019 Jun;114(5):439-443. doi: 10.1007/s00063-017-0346-1. Epub 2017 Sep 13.
5
Acute cardiorenal syndrome: Mechanisms and clinical implications.急性心肾综合征：机制与临床意义。
Cleve Clin J Med. 2018 Mar;85(3):231-239. doi: 10.3949/ccjm.85a.17019.
6
Cardiorenal syndrome: introduction.心肾综合征：引言
Clin J Am Soc Nephrol. 2013 Oct;8(10):1798-9. doi: 10.2215/CJN.06030613.
7
Toward Precision Medicine in the Cardiorenal Syndrome.迈向心脏肾脏综合征的精准医学。
Adv Chronic Kidney Dis. 2018 Sep;25(5):418-424. doi: 10.1053/j.ackd.2018.08.017.
8
[Progress on the therapeutic mechanism and strategies for patients with cardiorenal syndrome].
Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Dec;41(12):1075-8.
9
Cardiorenal syndrome and the role of ultrafiltration in heart failure.心肾综合征及超滤在心力衰竭中的作用
Curr Heart Fail Rep. 2013 Mar;10(1):81-8. doi: 10.1007/s11897-012-0129-1.
10
[CARDIORENAL SYNDROME: CLINICAL FEATURES, EARLY DIAGNOSIS AND TREATMENT AT FAMILY MEDICINE].[心肾综合征：家庭医学中的临床特征、早期诊断与治疗]
Acta Med Croatica. 2016 Dec;70(4-5):207-16.
本文引用的文献
1
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.聚磺苯乙烯钠用于心力衰竭患者接受肾素-血管紧张素-醛固酮系统抑制剂治疗时的高钾血症管理：DIAMOND 试验的设计和原理。
Eur J Heart Fail. 2022 Jan;24(1):230-238. doi: 10.1002/ejhf.2386. Epub 2021 Dec 9.
2
A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk.一项针对慢性血液透析伴高心血管风险患者的肺部超声引导治疗策略的随机多中心试验。
Kidney Int. 2021 Dec;100(6):1325-1333. doi: 10.1016/j.kint.2021.07.024. Epub 2021 Aug 19.
3
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.KDIGO 2021慢性肾脏病血压管理临床实践指南
Kidney Int. 2021 Mar;99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003.
4
Can the assessment of ultrasound lung water in haemodialysis patients be simplified?血液透析患者的超声肺水评估能否简化？
Nephrol Dial Transplant. 2021 Dec 2;36(12):2321-2326. doi: 10.1093/ndt/gfaa285.
5
Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.肾素-血管紧张素系统阻滞剂停药与慢性肾脏病不良结局。
Nephrol Dial Transplant. 2021 Sep 27;36(10):1893-1899. doi: 10.1093/ndt/gfaa300.
6
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.糜酶抑制剂法西拉宾在糖尿病肾病中的作用——CADA DIA 试验结果。
Nephrol Dial Transplant. 2021 Dec 2;36(12):2263-2273. doi: 10.1093/ndt/gfaa299.
7
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2020慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
8
The aftermath of coronavirus disease 2019: devastation or a new dawn for nephrology?2019冠状病毒病的后果：肾脏病学的浩劫还是新起点？
Nephrol Dial Transplant. 2020 Jun 1;35(6):904-907. doi: 10.1093/ndt/gfaa094.
9
Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.在真实世界人群中，肾素-血管紧张素-醛固酮系统抑制剂致高钾血症的风险及与治疗中断相关的因素。
Nephrol Dial Transplant. 2021 Apr 26;36(5):826-839. doi: 10.1093/ndt/gfz263.
10
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.聚磺苯乙烯钠（patiromer）对比安慰剂，以增加耐治疗高血压合并慢性肾脏病（CKD）患者使用螺内酯的可能性（AMBER）：一项 2 期、随机、双盲、安慰剂对照试验。
Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15.
Zotero 插件